enGene (NASDAQ:ENGN) Sees Large Volume Increase – Time to Buy?

Shares of enGene Holdings Inc. (NASDAQ:ENGN) saw unusually-strong trading volume on Thursday . Approximately 1,441,707 shares changed hands during trading, an increase of 223% from the previous session’s volume of 446,828 shares.The stock last traded at $7.4660 and had previously closed at $6.88.

More enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Strong clinical progress for lead candidate detalimogene voraplasmid — a 63% complete response rate at 3 months in NMIBC, favorable tolerability, and pivotal cohort enrollment above targets. Management plans a LEGEND cohort update at a spring medical conference and expects a BLA submission in H2 2026, which are clear binary catalysts that could drive the stock if results and the regulatory pathway remain favorable. enGene Holdings: Key Catalysts Incoming For 2026
• Positive Sentiment: HC Wainwright raised EPS forecasts across multiple 2026–2029 periods and reiterated a “Buy” rating with a $25 price target — the analyst cut loss expectations (improved EPS) for FY2026–2029 and lifted near‑term quarter forecasts, signaling improved underlying assumptions about development progress and cash runway that can support a higher valuation if milestones are met. MarketBeat: HC Wainwright raises estimates for enGene
• Neutral Sentiment: Industry/sector noise unrelated to enGene — coverage about automakers phasing out V6 engines is not relevant to ENGN’s biotech story and is unlikely to affect the stock’s near-term performance. Why Automakers Are Phasing Out V6 Engines
• Negative Sentiment: Valuation and execution risk remain — consensus still anticipates continued losses (negative EPS), the company must deliver confirmatory pivotal data and a successful BLA, and the stock is trading below its 50‑day moving average, leaving downside if upcoming updates disappoint or timelines slip. enGene profile and metrics

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Monday, March 9th. Citigroup reissued a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Oppenheimer cut their target price on enGene from $33.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday. Jefferies Financial Group assumed coverage on shares of enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $27.00 price objective on shares of enGene in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, enGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.86.

enGene Price Performance

The company’s 50 day moving average price is $9.39 and its 200 day moving average price is $8.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 11.75. The company has a market cap of $479.65 million, a price-to-earnings ratio of -3.18 and a beta of -0.29.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11. On average, equities research analysts predict that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC raised its position in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Siren L.L.C. bought a new position in shares of enGene during the fourth quarter worth about $30,126,000. Braidwell LP bought a new stake in enGene in the 3rd quarter valued at approximately $15,479,000. Janus Henderson Group PLC acquired a new position in enGene during the 4th quarter worth approximately $17,110,000. Finally, Cormorant Asset Management LP grew its stake in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after acquiring an additional 1,676,405 shares in the last quarter. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.